5‐fluoro‐deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long‐term outcomes in soft tissue sarcomas: Results from a prospective trial
An SUVmax reduction verified on FDG-PET/CT imaging after neoadjuvant chemotherapy was a strong predictor of long-term outcomes. Metabolic imaging at treatment completion identified responders, supporting continued therapy in initially nonresponsive patients and guiding personalized treatment strategies.
Authors
- Andrea P. Espejo Freire (ORCID: https://orcid.org/0000-0001-9903-0864)
- Denis R. Clohisy
- Christian M. Ogilvie (ORCID: https://orcid.org/0000-0003-2614-0565)
- Keith M. Skubitz (ORCID: https://orcid.org/0000-0002-0690-9595)
- Edward Y. Cheng (ORCID: https://orcid.org/0000-0001-6125-9671)
- Jerry Froelich (ORCID: https://orcid.org/0000-0002-1972-9868)
- J. Carlos Manivel (ORCID: https://orcid.org/0000-0001-8402-7750)
- Brenda J. Weigel (ORCID: https://orcid.org/0000-0003-1080-1402)
- L. Chinsoo Cho
- Kathryn E. Dusenbery
- Rich Evans
Institutions
- St. Jude Children's Research Hospital (US)
- University of Minnesota Medical Center (US)
- Minneapolis VA Medical Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1002/cncr.70129
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences